Medulloblastoma is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children. A subset of cases is associated with colon cancer and APC germline mutations (Turcot syndrome), and APC and b-catenin point mutations occur in up to 10% of sporadic cases, indicating the involvement of the Wnt pathway in the development of medulloblastoma. In 39 sporadic cerebellar medulloblastomas screeened for alterations in the AXIN1 gene, another component of the Wnt pathway, we found missense AXIN1 mutations in two tumours, CCC-TCC at codon 255 (exon 1, Pro-Ser) and TCT-TGT at codon 263 (exon 1, Ser-Cys). Furthermore, the A allele at the G/A polymorphism at nucleotide 16 in intron 4 was significantly over-represented in medulloblastomas (39 cases; G 0.76 vs-A 0.24) compared to healthy individuals (86 cases; G 0.91 vs A 0.09; P ¼ 0.0027). RT-PCR revealed large deletions in the AXIN1 gene in 5/12 (42%) medulloblastomas, consistent with a previous report. However, we observed such deletions at a similar frequency also in normal brain tissue (6/12, 50%). Since there are multiple complementary, inverted sequences present in the AXIN1 gene, these large deletions may represent RT-PCR errors due to stem-loop secondary structures.
Introduction
Medulloblastoma (WHO grade IV) is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children (Giangaspero et al., 2000) It has an incidence rate of 2-3 cases per million population per year (CBTRUS, 2002) and accounts for approximately 20% of pediatric CNS neoplasms (Kumar et al., 1990; Lantos et al., 2002) .
The most frequent genetic alteration in medulloblastomas is isochromosome 17q, which occurs in up to 50% of cases (Bigner et al., 1988; Griffin et al., 1988) and appears to cause LOH at 17; that is found in 30-45% of medulloblastomas (Cogen and McDonald, 1996) . Translocations, deletions, and duplications of chromosome 1 are also frequent (Bigner et al., 1988; Griffin et al., 1988) . Rearrangement of chromosome 1 often results in trisomy 1q without loss of 1p. Comparative genomic hybridization (CGH) revealed loss of 17p with gain of 17q as the most frequent finding (Schutz et al., 1996; Reardon et al., 1997; Avet-Loiseau et al., 1999) , in addition to losses on chromosomes 10q (41%) and 11(41%), and gain on chromosome 7 (44%). LOH on chromosome 17p occurs in 30-50% of medulloblastomas (James et al., 1990; Albrecht et al., 1994; Giangaspero et al., 2000) . The smallest deletions were observed at 17p13 that includes the TP53 locus, but the frequency of TP53 mutations in medulloblastomas is less that 10% (Badiali et al., 1993; Giangaspero et al., 2000) , suggesting that a yet unidentified tumoursuppressor gene is located on chromosome 17p distal to the TP53 locus. Defects in a developmental signalling pathway involving mammalian homologues of the Drosophila segment polarity gene, pathched (PTCH), are involved in a small subset (o10%) of medulloblastomas. Inactivating PTCH mutations occur in approximately 10% of sporadic medulloblastomas (Raffel et al., 1997; Wolter et al., 1997; Zurawel et al., 2000) and typically lead to a truncated protein, preferentially in the desmoplastic variant (Pietsch et al., 1997; Raffel et al., 1997; Wolter et al., 1997) .
Most medulloblastomas are sporadic, but a small number of cases are associated with colon cancer (Turcot syndrome) caused by APC germline mutations (Hamilton et al., 1995; Cavenee et al., 2000) . Several other studies have also indicated involvement of the Wnt pathway in at least a subset of medulloblastomas. Mutations in the b-catenin gene were found in 5-10% of cases (Zurawel et al., 1998; Eberhart et al., 2000; Huang et al., 2000) , and APC mutations were occasionally (4%) detected in medulloblastomas lacking b-catenin mutations (Huang et al., 2000) . Dahmen et al. (2001) screened for alterations of the AXIN1 (Axis inhibition Protein 1) gene, another component of the Wnt pathway, in 86 primary medulloblastomas and 11 medulloblastoma cell lines, and found large deletions in 12% of cases and one somatic point mutation.
In the present study, we screened 39 primary medulloblastomas for alterations in the AXIN1 gene. We observed an AXIN1 polymorphism that is significantly over-represented in medulloblastoma patients and were able to confirm the presence of occasional point mutations. We further present evidence that previously reported large AXIN1 deletions in medulloblastomas are likely to present RT-PCR artefacts, since they were also detected in normal brain tissue samples.
Results

AXIN1 mutations
SSCP followed by DNA sequencing revealed missense AXIN1 mutations in 2/39 (5%) medulloblastomas. One was CCC-TCC at codon 255 in exon 1 with the aminoacid substitution Pro-Ser, and another was TCT-TGT at codon 263 in exon 1 with the amino-acid substitution Ser-Cys (Figure 1 ). Both mutations were located in the APC binding region of the AXIN1 gene. In both cases, no APC and b-catenin mutations were detected in our previous study (Huang et al., 2000) .
In three other medulloblastomas, the following silent mutations were observed: TCG-TCA (Ser-Ser) at codon 465 in exon 5, CAG-CAA (Gln-Gln) at codon 597 in exon 5, and GGG-GGT (Gly-Gly) at codon 526 in exon 5. Normal tissue from the same patient with TCG-TCA at codon 465 did not contain this mutation, indicating that this is not a polymorphism. Normal tissue samples from the other two cases were not available.
AXIN1 polymorphism
We compared the frequency of three known AXIN1 polymorphisms in medulloblastomas with that in normal individuals; TCA/TCC (Ser/Ser) at nucleotide 94 (codon 31, exon 1): The allelic frequency in medulloblastomas was C/C (57%), A/C (33%), A/A (10%), corresponding to C 0.735 vs A 0.265, which was similar to normal individuals (T 0.785 vs A 0.215; P ¼ 0.5046). G/A at nucleotide 16 in intron 4 was observed as G/G (60%), A/G (32%), A/A (8%) in medulloblastomas (G 0.76 vs A 0.24). The frequency of A in medulloblastomas was significantly higher in normal individuals (G 0.91 vs A 0.09; P ¼ 0.0027). GAC/GAT (Asp/Asp) at nucleotide 874 (codon 291, exon 1): The allelic frequency in medulloblastomas was T/T (30%), C/T (40%), C/C (30%), corresponding to T 0.50 vs C 0.50, which was similar to the values in normal individuals (T 0.40 vs C 0.60; P ¼ 0.1686).
In addition, we identified a novel polymorphism GCT/GCC (Ala/Ala) at nucleotide 1942, (codon 657, exon 6). The allelic frequency in medulloblastomas was C/C 3%, T/C 23%, T/T 74% (C 0.15 vs T 0.85) in medulloblastomas, which was similar to that in normal individuals (C 0.23 vs T 0.77; P ¼ 0.1698).
AXIN1 deletions
For five medulloblastomas, we could amplify sequences covering exons 1-5 of the wild-type AXIN1 by RT-PCR (1640, 1331 or 1197 bp, depending on the different sense primer used). Of these, three cases showed several additional smaller bands (approximately 200-600 bp). Six bands from these three cases were cut out from the gel, purified and directly sequenced. Three bands from three cases were AXIN1 sequences with large deletions of different sizes (502-1002 bp: Figure 2 ), and three were non-specific bands. For 12 medulloblastomas, we could amplify sequences covering exons 5-10 of the wild-type AXIN1 (1316 bp) by RT-PCR. Seven cases showed several additional smaller bands. Of these, six bands were sequenced, and four bands from three cases were again AXIN1 sequences with large deletions of different sizes (840-1084 bp; Figure 2 ); 2 were nonspecific bands. Overall, five of 12 (42%) medulloblastomas analysed showed a large deletion in at least one fragment.
For 12 normal brain tissue samples, we could amplify sequences covering exons 1-5 of the wild-type AXIN1 by RT-PCR. Of these, 10 cases showed several additional smaller bands. We sequenced 11 bands, and found that five were AXIN1 sequences with large deletions (722-1429 bp) and six were nonspecific bands (Figure 2 ). For five normal brain tissue samples, we could amplify sequences covering exons 5-10 of the wild-type AXIN1 by RT-PCR. Of these, four cases showed additional bands. Of these, six were sequenced and 3 were AXIN1 sequences with large deletions (1009-1016 bp); the remaining were nonspecific (Figure 2) . Overall, six of 12 (50%) normal brain tissues analysed showed a large deletion in at at least one fragment.
Discussion
The Wnt pathway plays a crucial role during embryonal development and organogenesis through the control of cell proliferation and apoptosis (Itoh et al., 1998 ; Figure 1 Representative DNA sequencing of AXIN1 point mutations in medulloblastomas. One medulloblastoma contains a C-T transition in codon 255, and another contains a C-G mutation in codon 263 (reference NCBI: AF 009674) AXIN1 mutations in medulloblastomas N Baeza et al Lee et al., 1999; Tsuda et al., 1999) . Wnt signalling stabilizes and accumulates b-catenin which, after transfer from the cytoplasms to the nucleus, interacts with members of the LEF-TCF family of transcription factors, leading to activation of various target genes, including c-myc and cyclin D1 (Morin, 1999; Brantjes et al., 2002) . The APC gene, orignally identified as the target of germline mutations that cause familial adenomatous polyposis (Groden et al., 1991) , forms a complex with glycogen synthase kinase 3b (GSK-3b) and promotes b-catenin degradation, thereby regulating the level of b-catenin in the cytoplasm (Rubinfeld et al., 1996) .
Axin is another negative regulator of the Wnt pathway; it encodes an 862-amino-acid protein that is ubiquitously expressed in embryos and adult tissues, and which plays a role in the formation of the embryonic axis (Zeng et al., 1997) . Several domains of Axin interact with APC, b-catenin, GSK-3b, protein phosphatase 2 (PP2A) and Axin itself (Smalley et al., 1999; Akiyama, 2000) . Axin promotes the phosphorylation of serine and threonine encoded by exon 3 of b-catenin by forming a complex with APC and GSK-3b, thereby causing a downregulation of b-catenin Kishida et al., 1998; Yamamoto et al., 1999; Hinoi et al., 2000) . Axin simultaneously binds to b-caternin and GSK-3b, and blocks signalling stimulated by Wnt or by APC mutations (Sakanaka et al., 1998) .
AXIN1 expression can be a strong inducer of apoptosis. Adenovirus-mediated gene transfer of the wild-type AXIN1 induced apoptosis in liver and colon cancer cell lines that had accumulated b-catenin as a consequence of either APC, b-catenin, or AXIN1 mutations (Satoh et al., 2000) . Overexpression of Axin leads to apoptosis in several cell lines (Neo et al., 2000) . Transgenic mice with inducible expression of Axin in mammary gland and lymphoid tissues displayed massive apoptosis and abnormalities in these tissues (Hsu et al., 2001) .
AXIN1 mutations have been found in three of four hepatocellular carcinoma (HCC) cell lines and in five of 87 primary HCCs that lacked b-catenin mutations . Taniguchi et al. (2002) reported AXIN1 mutations in seven of 73 (10%) HCCs and two of 27 (7%) hepatoblastomas. AXIN1 mutation was also detected in an ovarian endometrioid adenocarcinoma with b-catenin accumulation (Wu et al., 2001 ). The present study shows that 5% of medulloblastomas contain AXIN1 mutations. They were located within the APC-binding domain and may decrease the ability of AXIN1 to bind APC, an interaction required for the downregulation of b-catenin. It is of interest to note that one of the mutations (C-T at codon 255; Pro-Ser) was identical to that previously reported in a medulloblastoma (Dahmen et al., 2001) . Taken together with previous reports on b-catenin and APC mutations (Zurawel et al., 1998; Eberhart et al., 2000; Huang et al., 2000) , the present study, like the report by Dahmen et al. (2001) suggests that disruption of the Wnt pathway through either b-catenin, APC, or AXIN1 mutations is involved in the evolution of a small, but significant fraction (approximately 10-15%) of medulloblastomas.
In the present study, we identified several AXIN1 polymorphisms in medulloblastomas. , we identified a novel polymorphism at codon 657 (GCT/GCC, Ala/Ala). We assessed whether any of polymorphisms are over-represented in medulloblastomas. Comparison of frequencies with 86 normal healthy individuals of G/A polymorphism at nucleotide 16 in intron 4 revealed that A was markedly over-represented in medulloblastomas (24%) compared with normal individuals (9%; P ¼ 0.0027). It remains to be shown whether this polymorphism is also associated with increased susceptibility to other CNS neoplasms.
In a significant subset of medulloblastomas, Dahmen et al. (2001) detected large deletions in the AXIN1 gene by RT-PCR. We were able to confirm this observation, but found such deletions at similar frequencies also in non-neoplastic, normal brain tissue. A possible explanation for this unusual observation comes from the study by Mader et al. (2001) , who by RT-PCR observed deletions in the coding sequences of the large subunit of ribonucleotide reductase (R1) mRNA of colon carcinomas. However, corresponding genomic alterations at the DNA level or an aberrant truncated protein were not detected. In contrast to reverse transcriptase, amplification with Taq DNA polymerase or C. therm. DNA polymerase did not produce deletions, suggesting template switching activity intrinsic to retroviral reverse transcriptases. Furthermore, the same deletion was observed in RT-PCR experiments when in vitro transcribed R1 mRNA was used. Mader et al. (2001) therefore suggest that two direct repeats adjacent to a strong stem-loop secondary structure flanking the deleted region are the most likely explantation of these artificial deletions. We also analysed AXIN1 sequences inside deletions observed after RT-PCR, and found multiple complementary inverted sequences which may indeed cause stem-loop secondary structures. In conclusion, the AXIN1 deletions in medulloblastomas reported by Dahmen et al. (2001) are likely to be artefacts caused by retroviral transcriptase-based PCR and therefore do not play a role in the development of medulloblastomas.
Materials and methods
Tumour samples and DNA extraction
A total of 39 medulloblastoma biopsy samples were obtained from the Department of Neuropathology, University Hospital Zu¨rich, Switzerland. The mean age of patients was 16712 years. Of them, 23 were males and 16 were females. A total of 27 tumours were fixed in buffered formalin and embedded in paraffin, and 12 tumours were frozen in liquid nitrogen and kept at À801C. DNA from paraffin sections was extracted as previously described (Watanabe et al., 1998) . DNA was extracted from frozen materials using TRIZOL (Gibco BRL, Cergy Pontoise, France), according to the manufacturer's instructions.
As controls, we used 10 nontumourous autoptic brain tissue samples (white and grey matter of the cerebrum, and cerebellum) from patients who died of diseases other than brain tumours. These samples were frozen and kept at À801C. DNA from white blood cells of 86 healthy Caucasians were used as controls for AXIN1 polymorphisms.
SSCP analyses and direct DNA sequencing
Prescreening for mutations was carried out by PCR-SSCP analysis of exons 1-10 of the AXIN1 gene, using 23 sets of primers previously described by Satoh et al. (2000) . Briefly, PCR was performed in a total volume of 10 ml, consisting of 1 ml of DNA solution, 1U of Taq DNA polymerase (Invitrogen, Cergy Pontoise, France), 1 mCi of [a-
33 P]dCTP (ICN Biomedicals, Inc., Costa Mesa, CA, USA; specific activity, 3000 Ci/mmol), 1.5-2 mm MgCl 2 , 0.2 mm of each dNTP, 0.2 mm of both sense and antisense primers, 10 mm Tris-HCL, pH 8.3, and 50 mm KCl in the T3 thermocycler (Biometra, Archamps, France), with an initial denaturing step at 951C for 5 min, followed by 35 cycles of denaturation at 951C for 1 min, annealing at 58-651C for 50 s, and polymerization at 721C for 50 s, and a final extension for 5 min at 721C. After amplification, PCR products were loaded on to a 6% nondenaturing polyacrylamide gel containing 8% glycerol, at 40 W for 4 h at room temperature with cooling by fan. Gels were dried at 801C and autoradiographed for 16-48 h.
DNA from samples that showed mobility shifts was reamplified using the same primers, purified with the Qiaquick PCR purification kit (Qiagen, Courtaboeuf, France), and sequenced using the Big Dye TM Terminator cycle sequencing kit (ABI PRISM, Applied Biosystems, CA, USA) and the ABI 3100 PRISM DNA sequencer (Applied Biosystems, CA, USA).
RT-PCR
Total RNA from medulloblastomas or normal brain tissues was isolated using TRIZOL (Gibco BRL, Cergy Pontoise, France). First-stand cDNA was prepared from total cellular RNA using a random hexadeoxynucleotide primer and SuperScript RNase H-reverse transcriptase (Gibco BRL, Cergy Pontoise, France). The quality of the extracted RNA was confirmed by amplification of a b-actin sequence (324 bp) using primers 5 0 -CAA CCG CGA GAA GAT GAC C-3 0 (sense) amd 5 0 -TCC AGG GCG ACA TAG CAC A-3 0 (antisense) (based on the sequence from Genbank, Accession number X 00351).
To amplify exons 1-5 (fragment 1) of the AXIN1 (NCBI AF009674), three different sense primers, all located in exon 1, were used: (a) 5 0 -GGG AGA ACT GGT GTC CAC AG -3 0 (nucleotides 199-218), (b) 5 0 -CCT GTG ACT CGA ACG AGG AG -3 0 (nucleotides 498-518) or (c) 5 0 -AAG CAG CTG ATC GAT CCT GC-3 0 (nucleotides 632-651) (sense). The sequence of antisense primer was 5 0 -CAT GGC TGT GTG GTT CCA-3 0 (nucleotides 1812-1829). To amplify exons 5-10 (fragment 2) of AXIN1, primer 5 0 -AGG CTA CTC AGA GAG TGT TGG-3 0 (sense, nucleotides 1842-1863) and 5 0 -GAG ACA AGC TGT GTT GAA GG-3 0 (antisense, nucleotides 3140-3159) were used. The PCR mixture contained 100 ng of cDNA as template in 1 Â PCR buffer, 1.5 mm MgCl 2, 0.3 mm of each dNTP, 0.3 mm of each sense and antisense primer, and 1 U of Platinum Taq DNA polymerase (Invitrogen, Cergy Pontoise,France). PCR was carried out at initial denaturation at 941C for 10 min, followed by 42 cycles of 60 s at 941C, 60 s at 611C (fragment 1) or 641C (fragment 2) and 1 min 40 s at 721C, then final elongation at 721C for 7 min. The PCR products were separated on a 2% agarose gel and stained with ethidium bromide. PCR products were excised from the gel, purified using Qiaquick gel purification system (Qiagen, Courtaboeuf, France), and then sequenced using the Big Dye TM Terminator cycle sequencing kit (ABI PRISM, Applied Biosystems, CA, USA) and the ABI 3100 PRISM DNA sequencer (Applied Biosystems, CA,USA). Analysis of the sequences were performed using the programme Palindrome on the Pasteur Institute wed site (http://www.pasteur.fr).
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